vTv Therapeutics Inc. (VTVT - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.53 –$2.03 in the past one-month time frame, witnessed a sharp increase yesterday.
The move came after the company made an exclusive licensing deal with Newsoara Biopharma for the rights to develop and commercialize one of its programs.
The company has seen estimate revision of no increase and two decreases over the past few months, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
vTv Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Another stock worth considering in the Medical - Biomedical and Genetics industry is Genomic Health, Inc. (GHDX - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is VTVT going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>